At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
Mesenchymal stromal cells +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Double-blind, Randomized, Controlled, Clinical Trial to Assess the Efficacy of Allogenic Mesenchymal Stromal Cells in Patients With Acute Respiratory Distress Syndrome Due to COVID-19
In Brief
A Phase 2 clinical trial evaluating Mesenchymal stromal cells and Placebo for Acute Respiratory Distress Syndrome and COVID-19 Pneumonia. Completed, enrolled 20 participants across 1 site.
Detailed Summary
A double-blind, randomized, controlled, clinical trial to evaluate the efficacy and safety of MSC (mesenchymal stromal cells) intravenous administration in patients with COVID-induced ARDS compared to a control arm.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSpain
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
Enrollment StartSep 2020
First PostedNov 2020
Primary CompletionJan 2022
Study CompletionFeb 2022
TodayJul 2026
First PostedNov 4, 2020
Enrollment StartSep 15, 2020
Primary CompletionJan 1, 2022
Study CompletionFeb 1, 2022
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 5.7 years ago
Interventions
Mesenchymal stromal cellsbiological
Administration of one single dose of allogenic Mesenchymal stromal cells
Placeboother
Administration of placebo (solution identical to experimental treatment, without the MSC)